CXCR2 Ligand Composition for Higher iPS Reprogramming Yield

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for producing induced pluripotent stem cells (iPS) face low efficiency and safety concerns due to the use of animal-derived materials, leading to contamination risks and high costs, while existing chemical and viral approaches have limited effectiveness.

Innovation Solution

A composition comprising CXCR2 (CXC chemokine receptor 2) or its ligands, such as GRO-α, GRO-β, GRO-γ, GCP-2, NAP-2, ENA-78, and IL-8, is used to increase dedifferentiation efficiency by upregulating CXCR2 expression in somatic cells, combined with a placenta-derived cell conditioned medium for culturing.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If conventional reprogramming methods are used to produce induced pluripotent stem cells, then stem cell production can be achieved, but the efficiency is very low (only about 10 iPS cells obtained from 5x10^4 somatic cells)

Engineering Contradiction:
ImproveiPS cell production efficiencyVSAvoidtime and resource investment for low-yield production
Core Design Contradiction:
ProductivityVSLoss of time

Solution Approach 1:

The invention changes the biochemical parameters of the culture system by introducing CXCR2 ligands (IL-8, GRO-α, GRO-β, GRO-γ, GCP-2, NAP-2, or ENA-78) at specific concentrations (e.g., 10-100 ng/mL) to activate CXCR2 signaling pathways, thereby transforming the cellular state from differentiated to pluripotent with dramatically improved efficiency

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The invention uses CXCR2 ligands as intermediary substances that mediate the transformation process from somatic cells to iPS cells. These ligands act as signaling molecules that trigger intracellular pathways (PI3K/Akt, MAPK/ERK) to induce dedifferentiation, serving as a bridge between conventional culture conditions and successful reprogramming

Inventive Principle:
Principle #24Intermediary (Mediator)

2Reliability

If animal-derived feeder cells or animal-derived gel coatings are used for stem cell culture, then cell proliferation and maintenance can be supported, but contamination with heteroproteins occurs leading to safety concerns

Engineering Contradiction:
Improvesafety of stem cell therapy productVSAvoidcontamination with heteroproteins
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention extracts and eliminates the harmful animal-derived components (feeder cells and gel coatings) from the culture system, replacing them with a defined chemical composition containing CXCR2 ligands that maintains culture support functions without introducing heteroprotein contamination risks

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The invention replaces expensive, complex animal-derived materials with a simple, defined chemical composition that can be easily prepared and discarded, eliminating the need for animal components while maintaining culture effectiveness and safety

Inventive Principle:
Principle #27Cheap short-living objects (Disposable)

3Productivity

If animal-derived feeder cells or special gel coatings are used for stem cell culture, then cell proliferation can be maintained, but the cost is high making it economically inadequate for mass production

Engineering Contradiction:
Improvemass production capabilityVSAvoidproduction cost
Core Design Contradiction:
ProductivityVSEase of manufacture

Solution Approach 1:

The invention replaces expensive animal-derived feeder cells and special gel coatings with a inexpensive defined chemical composition containing CXCR2 ligands, dramatically reducing production costs while enabling scalable mass production of iPS cells

Inventive Principle:
Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The invention changes the economic parameters of production by using a simple chemical composition that can be manufactured at low cost, transforming the process from an expensive, low-scale operation to an economically viable mass production system

Inventive Principle:
Principle #35Parameter changes

4Productivity

If versatile viruses, chemicals, or cytokines are used to increase dedifferentiated stem cell production, then production efficiency may be improved, but the effectiveness is limited and safety concerns remain

Engineering Contradiction:
Improvededifferentiated stem cell production efficiencyVSAvoidsafety and effectiveness of production method
Core Design Contradiction:
ProductivityVSReliability

Solution Approach 1:

The invention uses CXCR2 ligands as specific intermediary signaling molecules that target the CXCR2 receptor pathway, providing a more precise and effective alternative to non-specific viruses and chemicals, achieving high production efficiency with improved safety and reliability

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention changes the specificity and potency parameters of the production method by using targeted CXCR2 ligands instead of broad-spectrum viruses or chemicals, achieving superior effectiveness while maintaining safety through defined, controllable concentrations

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method significantly enhances the efficiency of dedifferentiation to induced pluripotent stem cells, reducing contamination risks and costs, and improving the scalability of stem cell production.

Implementation Method 1

the composition comprises CXCR2 (CXC chemokine receptor 2), which is a receptor on a human somatic cell

Methodology Applied
Scientific EffectReceptor-ligand binding:

Implementation Method 2

the ligand of CXCR2 is at least one selected from the group consisting of GRO-α (growth-regulated oncogene-α), GRO-β (growth-regulated oncogene-β), GRO-γ (growth-regulated oncogene-γ), GCP-2 (granulocyte chemotactic protein-2), NAP-2 (Neutrophil Activating Peptide-2), ENA-78 (Epithelial neutrophil-activating protein-78), and IL-8 (Interleukin-8)

Methodology Applied
Scientific EffectChemokine signaling:

Data Source

PatentEP3778874B1Composition for inducing dedifferentiation from somatic cells to induced pluripotent stem cells and method of inducing dedifferentiation using same
Publication Date: 2026.01.28 KOREA UNIV RES & BUSINESS FOUND
  • EP3778874B1 patent drawingFigure 1a
  • EP3778874B1 patent drawingFigure 1b
  • EP3778874B1 patent drawingFigure 1c

AI summary

The present invention relates to a composition for inducing dedifferentiation form somatic cells to induced pluripotent stem cells (iPSs) and method of inducing dedifferentiation using same, wherein the composition for inducing dedifferentiation and the method of inducing dedifferentiation increases the efficiency of dedifferentiation from somatic cells to iPSs by stimulating CXC chemokine receptor 2 (CXCR2), which is a receptor on human somatic ells, and thus may be effectively used for inducing the dedifferentiation to iPSs.